

19 March 2024

ASX Announcement

EXOSOMES FOR NON-INVASIVE PRE-NATAL TESTING

INOVIQ Limited (ASX:IIQ or **INOVIQ**) is pleased to announce a paper, co-authored by INOVIQ's Chief Scientific Officer (CSO) Professor Gregory Rice, entitled *IFPA Joan Hunt senior award in placentology lecture: Extracellular vesicle signalling and pregnancy* has been published online in *Placenta* and is available [here](#).

The paper highlights the use of extracellular vesicles (EV, including exosomes) for non-invasive prenatal testing to manage pregnancy complications and the critical need for specific and scalable exosome isolation methods, such as INOVIQ's EXO-NET and EXO-ACE exosome isolation technologies.

CSO Professor Rice said: *"The field of extracellular vesicle signalling has the potential to transform our understanding of maternal-fetal communication and points to new opportunities for non-invasive prenatal testing and therapeutic intervention. EVs have been implicated in implantation, placentation, maternal adaptation to pregnancy and complications of pregnancy, being detectable in maternal circulation as early as 6 weeks of pregnancy. Changes in EVs and their biomarkers might allow us to develop better diagnostics and therapeutics."*

CEO Dr Learne Hinch: *"Developing accurate and reliable EV-based diagnostics requires identification of disease-associated biomarkers and specific and scalable exosome isolation methods. Use of exosomes for non-invasive pre-natal testing to manage pregnancy complications is an exciting possibility and now within reach. INOVIQ has solved this key industry challenge with its proprietary EXO-NET and EXO-ACE technologies that enable fast, efficient and scalable exosome isolation for commercial applications in diagnostics and therapeutics."*

Authorised for release by the Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Learne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.